Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats
Tóm tắt
Disease states such as arthritis may interact with the kinetics of β-blockers. Acebutolol (AC) is a chiral β-blocker which is available as a racemate. The beneficial properties of AC, however, is attributed mainly to theS-(+)-enantiomer. The disposition of AC enantiomers and their active, chiral metabolites, diacetolol (DC) were examined after oral administration to healthy and adjuvant-induced arthritic (AA) female Sprague-Dawley rats. Arthritis was induced by tail base injection ofMycobacterium butyricum. Swelling of hind and forepaws were apparent in 10–16 days in AA but not controls. Control and AA rats were sacrificed at 0.5, 1, 2, 4, 6 and 8 h after a 25 mg/kg oral AC dose and blood was collected (n=6). Significant three to tenfold increases in the initial plasma concentrations (0.5–2h) of AC were observed in AA. Enantiomers were equally affected, thus ACS∶R ratio was not changed. Higher plasma concentrations of the metabolite were only significant at 2h. The ratio of DC∶AC, however, was unaffected by AA. The DCS∶R ratio was significantly decreased at 0.5 and 1 h in AA. The limited protein binding of AC (10%) was neither stereoselective nor affected by AA. Reduced intrinsic clearance in AA may be responsible for these observations.
Tài liệu tham khảo
E. D. Harris,Rheumatoid arthritis: the clinical spectrum. InTextbook of Rheumatology. (Eds. W. N. Kelly, E. D. Harris, S. Ruddy, et al.) pp. 928–963, WB Saunders, Philadelphia 1981.
F. M. Belpaire, M. G. Bogeart and M. Rosseneu,Binding of β-adrenoceptor blocking drugs to human serum albumin, to al-acid glycoprotein and to human serum. Eur. J. Clin. Pharmacol.22, 253–256 (1982).
T. Walle, J. G. Webb, E. E. Bagwell, K. Halle, H. B. Daniell and T. E. Gaffney,Stereoselective delivery and actions of beta receptor antagonists. Biochem. Pharmacol.,37, 115–124 (1988).
F. Jamali, R. Mehvar and F. M. Pasutto,Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. J. Pharm. Sci.78, 695–715 (1989).
M. W. Whitehouse,Adjuvant-induced polyarthritis in rats. InHandbook of Animal Models for the Rheumatic Diseases. Vol I. (Eds. R. Greenwald and H. Diamond) pp. 3–16. CRC Press, Boca Raton, Florida 1988.
H. Bishop, R. E. Schneider and P. Welling,Plasma propranolol concentrations in rats with adjuvant-induced arthritis. Biopharm. Drug Dispos.2, 291–297 (1981).
K. A. Walker, H. E. Barber and G. M. Hawksworth,Mechanism responsible for altered propranolol disposition in adjuvant-induced arthritis in the rat. Drug Metab. Dispos.14, 482–486 (1986).
F. M. Belpaire, F. De Smet, B. Chindavijak, N. Fraeyman and M. G. Bogaert,Effect of turpentine-induced inflammation on the disposition kinetics of propranolol, metoprolol, and antipyrine in the rat. Fundam. Clin. Pharmacol.3, 79–88 (1989).
B. Chindavijak, F. M. Belpaire, F. De Smet and M. G. Bogaert,Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat. J. Pharmacol. Exp. Ther.246, 1075–1079 (1988).
M. Yauhara, J. Fujiwara, S. Kitade, H. Katayama, K. Okumura and R. Hori,Effect of altered plasma protein on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery. J. Pharmacol. Exp. Ther.235, 513–520 (1985).
A. Roux, B. Flouvat, Y. Fouache and J. P. Bourdarias,Systemic bioavailability of acebutolol in man. Biopharm. Drug Dispos.4, 293–297 (1983).
T. J. Coombs, C. J. Coulson and V. J. Smith,Blood plasma binding of acebutolol and diacetolol in man. Br. J. Clin. Pharmac.9, 395–397 (1980).
M. Piquette-Miller, R. T. Foster, C. T. Kappagoda and F. Jamali,Pharmacokinetics of acebutolol enantiomers in man. J. Pharm. Sci.80, 313–316 (1991).
M. Piquette-Miller, R. T. Foster, F. M. Pasutto and F. Jamali,Stereospecific high-performance liquid chromographic assay of acebutolol in human plasma and urine. J. Chromatogr.526, 129–137 (1990).
M. Piquette-Miller and R. T. Foster,Stereospecific HPLC assay of diacetolol. J. Chromatogr.533, 300–303 (1990).
R. F. Collins and C. F. George,Studies on the disposition and fate of [14 C]-acebutolol in man and dog. Br. J. Clin. Pharmacol.3, 346P (1975).
P. J. Meffin, R. A. Winkle, F. A. Peters and D. C. Harrison,Dose-dependent acebutolol dispostion after oral administration. Clin. Pharmacol. Ther.24, 542–547 (1978).
M. Piquette-Miller, R. T. Foster, C. T. Kappagoda and F. Jamali,Effect of aging on the pharmacokinetics of acebutolol enantiomers. J. Clin. Pharmacol.32, 148–156 (1992).
R. E. Schneider, H. Bishop, M. J. Kendall and C. P. Quarternan,Effect of inflammatory disease on plasma concentrations of three β-adrenoceptor blocking agents. Int. J. Clin. Pharmacol. Ther. Tox.19, 158–162 (1981).
H. Mielants et al.Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. J. Rheumatology18, 394–400 (1991).
R. Gabriel, C. M. Kaye and M. G. Sankey,Preliminary observations on the excertion of acebutolol and its acetyl metabolite in the urine and faeces of man. J. Pharm. Pharmacol.33, 386–387 (1981).
B. J. Key, C. A. Mucklow and H. Bishop,The absorption of propranolol from the jejunum in rats with adjuvant-induced arthritis. Biopharm. Drug Dispos.7, 233–237 (1986).
C. F. George and B. S. Gruchy,Elimination of drugs by active intestinal transport. J. Pharm. Pharmacol.31, 643–644 (1979).
B. Chindavijak, F. M. Belpaire and M. G. Bogaert,In-vitro biotransformation of antipyrine, lignocaine and propranolol in the liver of rats with turpentine-induced inflammation. J. Pharm. Pharmacol.39, 883–886 (1987).
B. D. Andresen and F. T. Davis,Metabolism of acebutolold 6 in the rat correlates with the identification of a new metabolite in human urine. Drug Metab. Dispos.79, 360–365 (1979).